New Book "The Unseen Epidemic" Advocates Incorporating Dark Adaptation Testing to Improve Primary Eye Care

Henderson, NV, USA — EVOQ Technologies announced the publication of The Unseen Epidemic: Why Night Vision Loss Is the Canary in the Coal Mine for Retinal Health. Co-authored by Kasia Hein-Peters, M.D., CEO of EVOQ Technologies, and Daniel Lindgren, Founder and Chief Innovation Officer, and edited scientifically by Benjamin Bakall, M.D., Ph.D., the book explains how functional dark adaptation testing in primary eye care practices can significantly improve early retinal disease detection and management.

While standard visual acuity exams and structural imaging tools (such as OCT) excel at identifying established anatomical damage, The Unseen Epidemic demonstrates that rod photoreceptors fail first under metabolic stress. Adding functional testing alongside structural imaging enables clinicians to detect early retinal distress years before structural lesions appear on scans, establishing night vision loss as a vital functional biomarker.

In the book’s foreword, Joseph J. Pizzimenti, OD, FAAO, FORS, Professor at the University of the Incarnate Word, highlights the clinical value of the publication:

“Now available in both a long-form monograph and an abridged version, The Unseen Epidemic is a powerful clinical practice tool written for eye care physicians. This valuable resource will be required reading for my residents.”

Designed as a hands-on guide for primary eye care doctors, the book provides a practical framework for identifying candidates for dark adaptation testing, interpreting results, and deploying appropriate interventions based on clinical diagnosis and disease progression. It describes how to seamlessly incorporate dark adaptation testing into existing practice workflows and properly code and bill for diagnostic and screening tests.

For more information or to order the book, visit the official landing page at www.retinatesting.com or the book’s page on Amazon.

About EVOQ Technologies

Evoq Technologies is a privately held medical technology company developing wearable, cloud-connected functional diagnostics built on the proprietary SightGard™ cloud platform.

Based in Henderson, Nevada, EVOQ’s portfolio includes the Twilight™ Dark Adaptometer, which is FDA-registered and commercially available, and the investigational device SmartERG®. The company’s mission is to expand access to functional testing by eye care professionals for the earliest detection of retinal dysfunction, leading to interventions that help clinicians prevent vision loss before structural damage occurs.

Learn more at www.goevoq.com.

For more information, contact Evoq Technologies at 866.595.9594 or info@goevoq.com.